The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review-Reference-Cited by-同舟云学术

The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review

Published:2009-11 Issue:16 Volume:45 Page:2749-2758
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Jassem Jacek,Carroll Christopher,Ward Sue E.,Simpson Emma,Hind Daniel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. National Institute for Health and Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. Full Guideline. London: NICE; 2009.

2. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond;Esteva;Oncologist,2001

3. Targeting the microtubules in breast cancer beyond taxanes: The epothilones;Cortes;Oncologist,2007

4. Extending survival with chemotherapy in metastatic breast cancer;O’Shaughnessy;Oncologist,2005

5. Options for the treatment of patients with taxane-refractory metastatic breast cancer;Overmoyer;Clin Breast Cancer,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01);Cancer Research and Treatment;2019-01-15

2. Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis;Health Services Research;2018-07-24

3. Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm;JNCI: Journal of the National Cancer Institute;2017-10-05

4. Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts;Oncotarget;2017-02-11

5. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer;Advances in Experimental Medicine and Biology;2017